De novo Lipogenesis Protects Cancer Cells from Free Radicals and Chemotherapeutics by Promoting Membrane Lipid Saturation
Top Cited Papers
Open Access
- 13 October 2010
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (20), 8117-8126
- https://doi.org/10.1158/0008-5472.can-09-3871
Abstract
Activation of de novo lipogenesis in cancer cells is increasingly recognized as a hallmark of aggressive cancers and has been implicated in the production of membranes for rapid cell proliferation. In the current report, we provide evidence that this activation has a more profound role. Using a mass spectrometry–based phospholipid analysis approach, we show that clinical tumor tissues that display the lipogenic phenotype show an increase in the degree of lipid saturation compared with nonlipogenic tumors. Reversal of the lipogenic switch in cancer cells by treatment with the lipogenesis inhibitor soraphen A or by targeting lipogenic enzymes with small interfering RNA leads to a marked decrease in saturated and mono-unsaturated phospholipid species and increases the relative degree of polyunsaturation. Because polyunsaturated acyl chains are more susceptible to peroxidation, inhibition of lipogenesis increases the levels of peroxidation end products and renders cells more susceptible to oxidative stress–induced cell death. As saturated lipids pack more densely, modulation of lipogenesis also alters lateral and transversal membrane dynamics as revealed by diffusion of membrane-targeted green fluorescent protein and by the uptake and response to doxorubicin. These data show that shifting lipid acquisition from lipid uptake toward de novo lipogenesis dramatically changes membrane properties and protects cells from both endogenous and exogenous insults. These findings provide important new insights into the role of de novo lipogenesis in cancer cells, and they provide a rationale for the use of lipogenesis inhibitors as antineoplastic agents and as chemotherapeutic sensitizers. Cancer Res; 70(20); 8117–26. ©2010 AACR.Other Versions
This publication has 40 references indexed in Scilit:
- Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate CancerJNCI Journal of the National Cancer Institute, 2009
- Conjugated Linoleic Acid (CLA) Inhibits Expression of the Spot 14 (THRSP) and Fatty Acid Synthase Genes and Impairs the Growth of Human Breast Cancer and Liposarcoma CellsNutrition and Cancer, 2008
- Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of β-catenin in prostate cancerLaboratory Investigation, 2008
- Routes to 4-Hydroxynonenal: Fundamental Issues in the Mechanisms of Lipid PeroxidationOnline Journal of Public Health Informatics, 2008
- Inhibition of Fatty Acid Synthase Induces Endoplasmic Reticulum Stress in Tumor CellsCancer Research, 2007
- Induction of Apoptosis in Colorectal Carcinoma Cells Treated with 4-Hydroxy-2-nonenal and Structurally Related Aldehydic Products of Lipid PeroxidationChemical Research in Toxicology, 2004
- A Photoactivatable GFP for Selective Photolabeling of Proteins and CellsScience, 2002
- Effect of γ-linolenic acid on cellular uptake of structurally related anthracyclines in human drug sensitive and multidrug resistant bladder and breast cancer cell linesEuropean Journal of Cancer, 1999
- On the conformational, physical properties and functions of polyunsaturated acyl chainsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1991
- Effect of harvesting methods, growth conditions and growth phase on diacylglycerol levels in cultured human adherent cellsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1988